Sección de Cirugía Hepato-Bilio-Pancreática, Unidad de Trasplante Hepático, Servicio de Cirugía General y Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain.
Servicio de Urología, Hospital Universitario Gregorio Marañón, Madrid, Spain; Unidad de Trasplante Renal, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Actas Urol Esp (Engl Ed). 2021 Nov;45(9):587-596. doi: 10.1016/j.acuroe.2021.04.012. Epub 2021 Oct 23.
To evaluate the safety and efficacy of the retrohepatic inferior vena cava control through an anterior approach (RIVCA) technique in renal cell carcinoma (RCC) with level IIIa tumor thrombus.
Initial series of 6 cases presenting RCC and level IIIa tumor thrombus who underwent radical nephrectomy and tumor thrombectomy using the RIVCA technique between 2018-2019. RIVCA technique aims to gain complete control of the retrohepatic inferior vena cava above the cranial end of the tumor thrombus, but excluding the major hepatic veins in order to preserve the natural hepato-caval shunt. A step-by-step description of the procedure is provided. Disease features, operative characteristics, and surgical outcomes were registered prospectively.
Radical nephrectomy and tumor thrombectomy were completed in all cases. RIVCA technique did not increase operative time significantly (range: 14-22 min). Mean estimated blood loss was 325 cc (range: 250-400). Blood transfusion was not required intraoperatively in any of the cases. Mean postoperative transfusion rate was 1.3 red blood cells packed units (range: 0-2). There were no cases of intraoperative pulmonary embolism or major complications (Clavien-Dindo III-V) in the period of 30 days postoperatively. Median postoperative length of stay was 8 days (range: 5-11).
The RIVCA technique applied to cases of RCC and level IIIa tumor thrombus provides complete control of the retrohepatic inferior vena cava above the tumor thrombus cranial end, while prevents intraoperative hemodynamic instability by maintaining cardiac preload through the porto-caval shunt. This technique may limit operative morbidity (intraoperative pulmonary embolism and massive hemorrhage), thus becoming a helpful adjunct to be used in cases of RCC with level IIIa tumor thrombus.
评估通过前入路(RIVCA)技术控制肝后下腔静脉在肾细胞癌(RCC)伴 IIIa 级肿瘤血栓中的安全性和有效性。
2018 年至 2019 年期间,我们对 6 例 RCC 伴 IIIa 级肿瘤血栓患者进行了根治性肾切除术和肿瘤血栓切除术,采用 RIVCA 技术。RIVCA 技术旨在完全控制肿瘤血栓头端以上的肝后下腔静脉,但不包括主要肝静脉,以保留自然的肝静脉-下腔静脉分流。我们提供了该手术步骤的详细描述。前瞻性地记录了疾病特征、手术特点和手术结果。
所有患者均完成根治性肾切除术和肿瘤血栓切除术。RIVCA 技术并未显著增加手术时间(范围:14-22 分钟)。平均估计失血量为 325cc(范围:250-400)。所有患者术中均未输血。平均术后输血率为 1.3 个单位(范围:0-2)的红细胞浓缩悬液。术后 30 天内无术中肺栓塞或重大并发症(Clavien-Dindo III-V 级)。中位术后住院时间为 8 天(范围:5-11)。
应用于 RCC 伴 IIIa 级肿瘤血栓的 RIVCA 技术,可在肿瘤血栓头端以上完全控制肝后下腔静脉,同时通过门腔静脉分流维持心脏前负荷,防止术中血流动力学不稳定。该技术可能会降低手术发病率(术中肺栓塞和大出血),因此成为 RCC 伴 IIIa 级肿瘤血栓的一种有用的辅助治疗方法。